サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1780713

デュプイトレン病の世界市場

Dupuytren's Disease

出版日
ページ情報
英文 369 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
デュプイトレン病の世界市場
出版日: 2025年07月31日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 369 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

デュプイトレン病の世界市場は2030年までに107億米ドルに達する見込み

2024年に88億米ドルと推定されるデュプイトレン病の世界市場は、2024年から2030年にかけてCAGR 3.3％で成長し、2030年には107億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるタイプIは、CAGR 3.8%を記録し、分析期間終了時には63億米ドルに達すると予測されます。タイプIIセグメントの成長率は、分析期間中CAGR 2.6％と推定されます。

米国市場は24億米ドルと推定、中国はCAGR6.3％で成長予測

米国のデュプイトレン病市場は、2024年に24億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに21億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3%と2.6%と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

世界のデュプイトレン病市場- 主要動向と促進要因まとめ

デュプイトレン病がこれまで以上に臨床的に注目される理由とは？

手掌筋膜の慢性線維化疾患であるデュプイトレン病は、ニッチな外科的関心事から、治療への関心が高まる医療疾患として広く認知されるようになりました。かつては、高齢の白人男性に比較的限局した疾患と考えられていたが、最近の調査と診断の進歩により、さまざまな人口構成や地域にわたって、より広範な有病率が明らかになってきました。重篤な拘縮が生じる前に、結節や肥厚した腱索のような早期の症状を呈する患者が増加しているため、医師は早期発見と非侵襲的介入に一層力を入れています。デュプイトレン病は現在、単に手の変形としてだけでなく、ペイロニー病や五十肩などの他の疾患と病態生理学的経路を共有する可能性のある全身性の線維増殖性疾患として認識されています。このような関連性は、治療や診断に対するより総合的なアプローチを促しています。この疾患の陰湿な進行や、基本的な手の機能を制限する指の拘縮の心理社会的な影響も、ヘルスケア提供者に、消極的な外科的対応ではなく、長期的な管理戦略の開発を促しています。その結果、臨床ガイドラインも患者の期待も、タイムリーな治療への関与、予防的ケア、生活の質の向上をサポートするように進化しており、市場の成長と技術革新のための肥沃な土壌を作り出しています。

低侵襲性の選択肢はどのように治療の情勢を変えているのか？

従来のデュプイトレン病の治療は、開腹手術による筋膜切除術に大きく依存しており、長い回復期間、手術リスク、比較的高い再発率を伴うことが多くなりました。しかし、低侵襲治療の人気と臨床的検証の高まりにより、治療パラダイムは急速に変化しています。酵素注射、特にコラゲナーゼClostridium histolyticum（CCH）は、手術以外の画期的な選択肢として登場し、回復時間を大幅に短縮し、手技コストを下げながら、効果的な脊髄破壊を提供しています。もう一つの低侵襲手技である針腱切断術は、その簡便さ、即効性、外来で行えるという点で、専門医の間で勢いを増しています。これらのアプローチは、早期あるいは中等度の疾患症例にとって特に魅力的なものとなりつつあり、良好な安全性と有効性の結果を示す臨床研究の増加に支えられています。さらに、研究者らは線維芽細胞の活性を標的とし、筋線維芽細胞の増殖を抑える新規薬剤を探索しており、疾患の自然経過を変える可能性があります。このような非外科的選択肢の増加は、治療を整形外科専門医から皮膚科医、リウマチ専門医、一般開業医を含むより幅広い医療分野へとシフトさせ、市場の拡大をもたらしています。このような代替治療の利用可能性は、患者の治療に変革をもたらすだけでなく、慢性筋骨格系疾患に対するヘルスケアシステム戦略を再定義するものでもあります。

ニッチでありながら拡大するこの分野における地域差と市場セグメンテーションの原動力は何か？

デュプイトレン病は、多くの地域では稀な疾患と考えられているにもかかわらず、顕著な地理的・民族的ばらつきが見られ、それが市場の細分化と治療需要に影響を与えています。この疾患は、特にバイキングを祖先とする北欧の人々に最も多く見られるが、北米やアジアの一部では診断率が上昇しており、世界の負担が十分に認識されていないことを示唆しています。アルコール摂取、喫煙、糖尿病有病率、職業的負担などのライフスタイルが危険因子であると考えられ、地域的なヘルスケアキャンペーンの焦点になりつつあります。ドイツ、英国、米国など、高齢化が進み医療制度が発達している国では、費用対効果の高い外来治療やフォローアップケアに対する需要が大きいです。逆に新興市場は、認知度の向上、ヘルスケア資金の増加、医学会議や遠隔医療を通じたベストプラクティスの世界的普及により、徐々に追いついてきています。また、早期介入キットから治療後のリハビリ補助具まで、疾患の特定の段階に対応した新しい機器や治療ツールが開発されるにつれて、市場の細分化も顕著になっています。さらに、地域ごとの支払者の嗜好や保険適用方針が、さまざまな治療法の利用しやすさと手頃な価格の両方に影響を及ぼしており、地域ごとの政策枠組みが市場戦略計画の重要な要素となっています。

デュプイトレン病治療市場の勢いを加速させているものは何か？

デュプイトレン病治療市場の成長は、治療法の革新、臨床慣行の変化、患者行動の進化に関連するいくつかの要因によって牽引されています。主な促進要因のひとつは、コラゲナーゼ注射や針腱切開などの低侵襲技術の採用拡大であり、これによって以前は手術を避けていた患者の間で治療への関心が高まっています。より優れた診断ツールや医師の意識の向上により、早期病変が広く認識されるようになったことで、早期介入が行われるようになり、それに伴い外来治療の需要も増加しています。医療画像やデジタルヘルスプラットフォームの技術的進歩は、より正確な診断、治療計画、長期的なモニタリングを可能にし、ひいては再発率を低下させ、患者の満足度を向上させています。さらに、先進国を中心とした世界の高齢化がリスク集団の拡大に寄与しており、糖尿病や喫煙関連疾患などの併存疾患が罹患率をさらに押し上げています。新興国市場におけるヘルスケア・インフラの改善と可処分所得の増加も、特に欧米の治療モデルが採用されている地域では、これまで未開拓だった市場を掘り起こしつつあります。消費者側では、手指の可動性、職場の生産性、美観に対する意識の高まりが、早期治療を求める個人を後押ししています。これらの力学が相まって、デュプイトレン病治療市場は力強い成長を遂げ、イノベーションとアクセシビリティのための新たな道が開かれつつあります。

セグメント

疾患タイプ（i型、II型、III型）;タイプ（診断、治療）;エンドユーザー（病院、クリニック、学術・研究機関、その他）

調査対象企業の例

  • Actiza Pharmaceutical Pvt. Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • BioSpecifics Technologies Corp.
  • Bristol-Myers Squibb Company
  • Endo International plc
  • Fortress Biotech, Inc.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc（GSK）
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Nantong Jinghua Pharmaceutical Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Spear Pharmaceuticals
  • 180 Life Sciences Corp.
  • West-Ward Pharmaceuticals
  • Xian Janssen Pharmaceutical Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP30626

Global Dupuytren's Disease Market to Reach US$10.7 Billion by 2030

The global market for Dupuytren's Disease estimated at US$8.8 Billion in the year 2024, is expected to reach US$10.7 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Type I, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Type II segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 6.3% CAGR

The Dupuytren's Disease market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Dupuytren's Disease Market - Key Trends & Drivers Summarized

Why Is Dupuytren’s Disease Attracting Greater Clinical Attention Than Ever Before?

Dupuytren’s disease, a chronic fibrosing condition of the palmar fascia, has evolved from being a niche surgical concern to a widely acknowledged medical disorder with increasing therapeutic interest. Once considered a relatively localized issue among older Caucasian males, recent research and diagnostic advances have revealed its broader prevalence across different demographics and geographic regions. As more patients present with earlier-stage symptoms such as nodules and thickened cords before severe contracture sets in, physicians are focusing more on early detection and non-invasive intervention. Dupuytren’s disease is now recognized not merely as a hand deformity but as a systemic fibroproliferative disorder that may share pathophysiological pathways with other conditions such as Peyronie’s disease and frozen shoulder. These associations are encouraging a more holistic approach to treatment and diagnosis. The disease’s insidious progression and the psychosocial impact of finger contracture-limiting basic hand function-are also prompting healthcare providers to develop long-term management strategies, rather than reactive surgical responses. Consequently, both clinical guidelines and patient expectations are evolving to support timely therapeutic engagement, preventive care, and improved quality of life, creating fertile ground for market growth and innovation.

How Are Minimally Invasive Options Reshaping the Treatment Landscape?

Traditional treatment of Dupuytren’s disease was heavily reliant on open surgical fasciectomy, a procedure often associated with long recovery periods, surgical risks, and relatively high recurrence rates. However, the therapeutic paradigm is shifting rapidly due to the growing popularity and clinical validation of minimally invasive treatments. Enzymatic injections, especially collagenase clostridium histolyticum (CCH), have emerged as a revolutionary non-surgical option, offering effective cord disruption with significantly reduced recovery times and lower procedural costs. Needle aponeurotomy, another minimally invasive technique, is gaining momentum among specialists for its simplicity, immediate results, and the ability to be performed in outpatient settings. These approaches are becoming particularly appealing for early-stage or moderate disease cases and are being supported by an increasing number of clinical studies showcasing favorable safety and efficacy outcomes. Additionally, researchers are exploring novel agents that target fibroblast activity and reduce myofibroblast proliferation, potentially altering the natural course of the disease. This rise in non-surgical options is also shifting treatment from orthopedic specialists to broader segments of the medical community, including dermatologists, rheumatologists, and general practitioners, thereby expanding market reach. The availability of these alternative treatments is not only transforming patient care but also redefining healthcare system strategies for chronic musculoskeletal conditions.

What Drives Regional Variability and Market Segmentation in This Niche Yet Expanding Field?

Despite being considered a rare condition in many regions, Dupuytren’s disease shows notable geographic and ethnic variation that is influencing market segmentation and treatment demand. The condition remains most prevalent in Northern European populations, particularly among those with Viking ancestry, but increasing diagnosis rates in North America and parts of Asia are suggesting an under-recognized global burden. Lifestyle factors such as alcohol consumption, smoking, diabetes prevalence, and occupational strain appear to be contributory risk factors and are becoming focal points for regional healthcare campaigns. In countries with aging populations and advanced healthcare systems, such as Germany, the UK, and the US, there is significant demand for cost-effective outpatient treatments and follow-up care options. Conversely, emerging markets are gradually catching up due to better awareness, increased healthcare funding, and the global dissemination of best practices through medical conferences and telemedicine. Market segmentation is also becoming more pronounced as new devices and therapeutic tools are developed for specific stages of the disease, from early intervention kits to specialized post-treatment rehabilitation aids. Additionally, payer preferences and insurance coverage policies across regions are influencing both the accessibility and affordability of different treatment modalities, making regional policy frameworks a key component in market strategy planning.

What Is Fueling the Rising Momentum in the Dupuytren’s Disease Treatment Market?

The growth in the Dupuytren’s disease treatment market is driven by several factors related to therapeutic innovation, shifting clinical practices, and evolving patient behavior. One of the primary drivers is the expanding adoption of minimally invasive techniques such as collagenase injections and needle aponeurotomy, which are increasing treatment uptake among patients who previously avoided surgery. The broader recognition of early-stage disease, aided by better diagnostic tools and increased physician awareness, is leading to earlier intervention and a corresponding rise in demand for outpatient therapies. Technological advancements in medical imaging and digital health platforms are enabling more precise diagnosis, treatment planning, and long-term monitoring, which in turn are reducing recurrence rates and improving patient satisfaction. Additionally, an aging global population, particularly in developed nations, is contributing to a larger at-risk cohort, while comorbidities like diabetes and smoking-related disorders are further inflating incidence rates. Healthcare infrastructure improvements and rising disposable incomes in developing regions are also unlocking previously untapped markets, especially where Western treatment models are being adopted. On the consumer side, growing awareness around hand mobility, workplace productivity, and aesthetic concerns is encouraging individuals to seek earlier treatment, while payer systems in many countries are expanding coverage for non-surgical therapies. Collectively, these dynamics are driving robust growth in the Dupuytren’s disease treatment market and opening new avenues for innovation and accessibility.

SCOPE OF STUDY:

The report analyzes the Dupuytren's Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Type I, Type II, Type III); Type (Diagnosis, Treatment); End-Use (Hospitals, Clinics, Academic & Research Institute, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Actiza Pharmaceutical Pvt. Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • BioSpecifics Technologies Corp.
  • Bristol-Myers Squibb Company
  • Endo International plc
  • Fortress Biotech, Inc.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc (GSK)
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Nantong Jinghua Pharmaceutical Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Spear Pharmaceuticals
  • 180 Life Sciences Corp.
  • West-Ward Pharmaceuticals
  • Xian Janssen Pharmaceutical Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Dupuytren's Disease - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Early Diagnosis Throws the Spotlight on Dupuytren's Disease as a Manageable Hand Disorder
    • Aging Population and Increased Incidence Among Older Adults Propel Demand for Effective Treatment Options
    • Minimally Invasive Therapies and Non-Surgical Interventions Spur Growth in Patient-Centric Treatment Approaches
    • Innovation in Collagenase Clostridium Histolyticum Injections Strengthens the Business Case for Outpatient Procedures
    • Growing Focus on Hand Function and Quality of Life Accelerates Adoption of Early-Stage, Less Invasive Therapies
    • Reintroduction of Collagenase-Based Therapies in Key Markets Expands the Addressable Market for Recurrence-Prone Cases
    • Surgical Advancements and Post-Operative Rehabilitation Solutions Drive Demand in Advanced and Refractory Disease Stages
    • Development of Combination Therapies and Adjunctive Treatments Generates Opportunities for Long-Term Disease Management
    • Rising Use of Ultrasound and Imaging-Guided Interventions Enhances Precision in Minimally Invasive Treatment Delivery
    • Globalization of Specialty Care and Medical Tourism Opens New Markets for Advanced Dupuytren's Disease Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Dupuytren's Disease Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Dupuytren's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Dupuytren's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Dupuytren's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Type I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Type I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Type I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Type II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Type II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Type II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Type III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Type III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Type III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Academic & Research Institute by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Academic & Research Institute by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Academic & Research Institute by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • JAPAN
    • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • CHINA
    • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • EUROPE
    • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Dupuytren's Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Dupuytren's Disease by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • FRANCE
    • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • GERMANY
    • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Dupuytren's Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Dupuytren's Disease by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • INDIA
    • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Dupuytren's Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Dupuytren's Disease by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Dupuytren's Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Dupuytren's Disease by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
  • AFRICA
    • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030

IV. COMPETITION